Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CU06-1004 in Diabetic Macular Edema
NCT07459829Phase 2Not yet recruiting
- Sponsor
- Curacle Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Jan 2028
01
Overview
Phase 2, randomised, double-blind trial of CU06-RE in diabetic macular edema (DME) (3 arms), sponsored by Curacle Co., Ltd. Primary endpoint: Best Corrected Visual Acuity at 24 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CU06-RE
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07459829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459829.